Laboratory thrombophilias and venous thromboembolism

被引:10
作者
Joffe, HV [1 ]
Goldhaber, SZ [1 ]
机构
[1] Harvard Univ, Brigham & Womens Hosp, Div Cardiovasc, Dept Med,Sch Med, Boston, MA 02115 USA
关键词
genetic; hypercoagulability; inherited; thrombophilia; venous thromboembolism;
D O I
10.1191/1358863x02vm426ra
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Inherited abnormalities of coagulation are, increasingly recognized in patients with venous thromboembolism. Common causes of hypercoagulability, also known as thrombophilia, include factor V Leiden, the prothrombin gene mutation, hyperhomocysteinemia, and antiphospholipid antibodies. Thrombophilia should be suspected in patients who develop idiopathic venous thromboembolism at a young age, recurrent thrombosis, thromboses at unusual sites, recurrent unexplained pregnancy loss, or if there, is a family history of thrombotic disorders. The most cost-effective approach is to initially screen for factor V Leiden, the prothrombin gene mutation, hyperhomocysteinemia, and antiphospholipid antibodies because these are the most common defects causing thrombophilia. Long-term anticoagulation is controversial but should., be considered if unprovoked venous thromboembolism recurs.
引用
收藏
页码:93 / 102
页数:10
相关论文
共 63 条
[1]   Activation markers of coagulation and fibrinolysis in twins:: heritability of the prethrombotic state [J].
Ariëns, RAS ;
de Lange, M ;
Snieder, H ;
Boothby, M ;
Spector, TD ;
Grant, PJ .
LANCET, 2002, 359 (9307) :667-671
[2]  
Arnout J, 1996, THROMB HAEMOSTASIS, V75, P536
[3]   MUTATION IN BLOOD-COAGULATION FACTOR-V ASSOCIATED WITH RESISTANCE TO ACTIVATED PROTEIN-C [J].
BERTINA, RM ;
KOELEMAN, BPC ;
KOSTER, T ;
ROSENDAAL, FR ;
DIRVEN, RJ ;
DERONDE, H ;
VANDERVELDEN, PA ;
REITSMA, PH .
NATURE, 1994, 369 (6475) :64-67
[4]   Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects [J].
Bloemenkamp, KWM ;
Rosendaal, FR ;
Helmerhorst, FM ;
Vandenbroucke, JP .
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (01) :49-52
[5]   Factor V Leiden paradox: risk of deep-vein thrombosis but not of pulmonary embolism [J].
Bounameaux, H .
LANCET, 2000, 356 (9225) :182-183
[6]  
BRANDT JT, 1995, THROMB HAEMOSTASIS, V74, P1185
[7]   Risk of venous thromboembolism and clinical manifestations in carriers of antithrombin, protein C, protein S deficiency, or activated protein C resistance - A multicenter collaborative family study [J].
Bucciarelli, P ;
Rosendaal, FR ;
Tripodi, A ;
Mannucci, PM ;
De Stefano, V ;
Palareti, G ;
Finazzi, G ;
Baudo, F ;
Quintavalla, R .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1999, 19 (04) :1026-1033
[8]   ACQUIRED ANTITHROMBIN-III DEFICIENCY - LABORATORY DIAGNOSIS, INCIDENCE, CLINICAL IMPLICATIONS, AND TREATMENT WITH ANTITHROMBIN-III CONCENTRATE [J].
BULLER, HR ;
TENCATE, JW .
AMERICAN JOURNAL OF MEDICINE, 1989, 87 (3B) :S44-S48
[9]  
DAngelo A, 1997, BLOOD, V90, P1
[10]   The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation [J].
De Stefano, V ;
Martinelli, I ;
Mannucci, PM ;
Paciaroni, K ;
Chiusolo, P ;
Casorelli, I ;
Rossi, E ;
Leone, G .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (11) :801-806